drugset
drugset / Trial / NCT03935724

Stem Cells in Spinal Cord Injury

NCT03935724 ↗

Phase 2/3 Unknown 16 enrolled Neuroplast
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled and delayed-start phase II/III clinical study.

Timeline

Start
2022-01-18
Primary completion
2024-02-01
Completion
2024-08-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Neuro-Cells Cell therapy — Other

Indications

paraplegia spinal cord injury